NASDAQ:CDXC - ChromaDex Stock Price, Price Target & More

$4.24 +0.09 (+2.17 %)

(As of 04/24/2018 04:33 AM ET)

Previous Close$4.24

Today's Range$4.0933 - $4.30

52-Week Range$2.27 - $7.24

Volume130,878 shs

Average Volume453,240 shs

Market Capitalization$227.57 million

P/E Ratio-12.11

Dividend YieldN/A

Beta1.04

About ChromaDex (NASDAQ:CDXC)

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CDXC

CUSIPN/A

Webwww.chromadex.com

Phone949-419-0288

Debt

Debt-to-Equity Ratio0.01%

Current Ratio7.08%

Quick Ratio6.36%

Price-To-Earnings

Trailing P/E Ratio-12.11

Forward P/E Ratio-30.29

P/E GrowthN/A

Sales & Book Value

Annual Sales$21.20 million

Price / Sales10.97

Cash FlowN/A

Price / CashN/A

Book Value$1.00 per share

Price / Book4.24

Profitability

EPS (Most Recent Fiscal Year)($0.35)

Net Income$-11,370,000.00

Net Margins-48.68%

Return on Equity-52.15%

Return on Assets-40.36%

Miscellaneous

Employees74

Outstanding Shares54,840,000

How to Become a New Pot Stock Millionaire

ChromaDex (NASDAQ:CDXC) Frequently Asked Questions

What is ChromaDex's stock symbol?

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

How were ChromaDex's earnings last quarter?

ChromaDex (NASDAQ:CDXC) released its quarterly earnings results on Thursday, March, 8th. The company reported ($0.17) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.17). The business had revenue of $7.53 million for the quarter, compared to the consensus estimate of $7.50 million. ChromaDex had a negative net margin of 48.68% and a negative return on equity of 52.15%. View ChromaDex's Earnings History.

When is ChromaDex's next earnings date?

ChromaDex is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for ChromaDex.

What price target have analysts set for CDXC?

2 brokers have issued 1-year price targets for ChromaDex's shares. Their forecasts range from $7.00 to $8.00. On average, they expect ChromaDex's stock price to reach $7.50 in the next twelve months. View Analyst Ratings for ChromaDex.

What are Wall Street analysts saying about ChromaDex stock?

Here are some recent quotes from research analysts about ChromaDex stock:

1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (4/17/2018)
2. HC Wainwright analysts commented, "We note that the company’s revenues came in at $5.3M vs. our original forecast of $8M, while a net loss of $2.7M or $0.07 per share was also recorded vs. our projection for a positive EPS of $0.04. While R&D spending in the quarter was roughly in-line with our estimate at $728K vs. $700K, we note that COGS were slightly worse than our estimate, coming in at 57% vs. our projection of 49%. Given what we see as the current status of ChromaDex’s ingredients business, we have revised our 2017 revenue number to $24.3M, while we now project a net loss per share for 2017 of $0.14 vs. our prior forecast for EPS of $0.16 for the year." (8/11/2017)

Who are some of ChromaDex's key competitors?

Some companies that are related to ChromaDex include Foamix Pharmaceuticals (FOMX), MediWound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), PharmaCyte Biotech (PMCB), China Jo-Jo Drugstores (CJJD), Glg Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), Nutra Pharma (NPHC), FitLife Brands (FTLF), True Drinks (TRUU), Tauriga Sciences (TAUG), Entia Biosciences (ERGO) and Rock Creek Pharmaceuticals (RCPIQ).

Who are ChromaDex's key executives?

ChromaDex's management team includes the folowing people:

Mr. Frank Louis Jaksch Jr., Co-Founder, Chief Exec. Officer and Director (Age 50)
Mr. Robert N. Fried, Pres, Chief Strategy Officer, COO and Director (Age 58)
Mr. Thomas C. Varvaro, Consultant (Age 48)
Mr. Troy Allen Rhonemus, Exec. VP (Age 45)
Mr. Kevin M. Farr, Chief Financial Officer (Age 60)

Has ChromaDex been receiving favorable news coverage?

Press coverage about CDXC stock has trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ChromaDex earned a media sentiment score of 0.22 on Accern's scale. They also gave news articles about the company an impact score of 45.35 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of ChromaDex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChromaDex's stock price today?

One share of CDXC stock can currently be purchased for approximately $4.24.

How big of a company is ChromaDex?

ChromaDex has a market capitalization of $227.57 million and generates $21.20 million in revenue each year. The company earns $-11,370,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. ChromaDex employs 74 workers across the globe.

How can I contact ChromaDex?

ChromaDex's mailing address is 10005 Muirlands Blvd. Suite G, IRVINE CA, 92618. The company can be reached via phone at 949-419-0288 or via email at [email protected]

MarketBeat Community Rating for ChromaDex (CDXC)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		127 (Vote Outperform)
Underperform Votes:		98 (Vote Underperform)
Total Votes:		225

MarketBeat's community ratings are surveys of what our community members think about ChromaDex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.

ChromaDex (NASDAQ:CDXC) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for ChromaDex in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 76.89%. The high price target for CDXC is $8.00 and the low price target for CDXC is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$7.50	$7.50	$7.50	$6.3333
Price Target Upside:	76.89% upside	55.28% upside	32.74% upside	47.29% upside

ChromaDex (NASDAQ:CDXC) Consensus Price Target History

Price Target History for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ:CDXC) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/2/2018	HC Wainwright	Set Price Target	Buy	$8.00	High
9/25/2017	Ladenburg Thalmann	Initiated Coverage	Buy -> Buy	$7.00	N/A
1/3/2017	Rodman & Renshaw	Initiated Coverage	Buy	$6.00	N/A

(Data available from 4/24/2016 forward)

ChromaDex (NASDAQ:CDXC) Earnings History and Estimates Chart

Earnings by Quarter for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ:CDXC) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $0.02 EPS

ChromaDex (NASDAQ CDXC) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018		($0.03)					N/A
3/8/2018	Q4 2017	($0.17)	($0.17)	$7.50 million	$7.53 million	View	Listen
11/9/2017	Q3 2017	($0.05)	($0.07)	$6.50 million	$6.09 million	View	N/A
8/10/2017	Q2 2017	$0.04	($0.05)	$11.00 million	$5.31 million	View	N/A
5/11/2017	Q1 2017	$0.01	($0.05)	$8.00 million	$4.45 million	View	N/A
3/16/2017	Q4 2016	($0.01)	($0.06)	$5.60 million	$5.64 million	View	N/A
11/10/2016	Q3 2016		($0.03)		$5.01 million	View	Listen
8/11/2016	Q216		$0.01	$6.10 million	$8.80 million	View	Listen
5/12/2016	Q116		$0.01	$5.30 million	$7.30 million	View	Listen
3/17/2016	Q4 2015		($0.03)		$4.36 million	View	N/A
5/14/2015	Q1 2015		($0.03)		$5.26 million	View	N/A
11/6/2014	Q3 2014		($0.03)		$4.14 million	View	N/A
8/12/2014	Q2 2014		($0.06)		$3.86 million	View	N/A
5/8/2014	Q1 2014		($0.06)		$3.07 million	View	N/A
11/21/2013	Q3 13		($0.01)		$2.72 million	View	N/A
8/13/2013	Q2 2013		($0.03)		$2.71 million	View	N/A
5/10/2013	Q1 2013		$0.03		$2.34 million	View	N/A
3/29/2013	Q4 2012		($0.06)			View	N/A
11/8/2012	Q3 2012	($0.06)	($0.06)			View	N/A
8/9/2012	Q2 2012	($0.12)	($0.13)			View	N/A
5/10/2012	Q1 2012	($0.09)	($0.16)			View	N/A
3/15/2012	Q4 2011	($0.09)	($0.10)			View	N/A
11/10/2011	Q3 2011	($0.09)	($0.10)			View	N/A
8/11/2011	Q2 2011		($0.08)			View	N/A
5/12/2011	Q1 2011		($0.05)			View	N/A
3/16/2011	Q4 2010		($0.03)			View	N/A
11/16/2010	Q3 2010		($0.03)			View	N/A
8/17/2010	Q2 2010		($0.02)			View	N/A
3/31/2010	Q4 2009		($0.01)			View	N/A
11/17/2009	Q3 2009		($0.02)			View	N/A
8/18/2009	Q2 2009		($0.03)			View	N/A
5/15/2009	Q1 2009		($0.03)			View	N/A

(Earnings results data provided by Zacks Investment Research)

ChromaDex (NASDAQ:CDXC) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

ChromaDex (NASDAQ CDXC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.59%
Institutional Ownership Percentage: 10.14%

Insider Trading History for ChromaDex (NASDAQ:CDXC)

Institutional Ownership by Quarter for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ CDXC) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/29/2018	Frank L Jaksch Jr	CEO	Sell	474	$4.60	$2,180.40
3/27/2018	Frank L Jaksch Jr	CEO	Sell	24,578	$4.60	$113,058.80
1/11/2018	Frank L Jaksch Jr	CEO	Sell	28,379	$6.52	$185,031.08
12/21/2017	Frank L Jaksch Jr	CEO	Sell	58,400	$6.19	$361,496.00
11/17/2017	River Ventures Ltd Champion	Major Shareholder	Buy	731,707	$4.10	$2,999,998.70
8/25/2017	Stephen R Allen	Director	Buy	2,000	$3.31	$6,620.00	7,000
8/18/2017	Step Holdings Ltd Pioneer	Major Shareholder	Buy	786,167	$2.60	$2,044,034.20
8/15/2017	Robert N Fried	Insider	Buy	10,000	$3.15	$31,500.00	583,241
5/24/2017	Step Holdings Ltd Pioneer	Major Shareholder	Buy	2,521,526	$2.60	$6,555,967.60
5/19/2017	Stephen R Allen	Director	Buy	3,000	$3.20	$9,600.00	5,000
3/20/2017	Stephen R Allen	Director	Buy	2,000	$2.81	$5,620.00	2,000
12/12/2016	Frank L Jaksch Jr	CEO	Buy	2,000	$2.42	$4,840.00	201,557
9/1/2016	Frank L Jaksch Jr	CEO	Buy	1,500	$3.32	$4,980.00	199,557
9/1/2016	Robert N Fried	Director	Buy	15,000	$3.39	$50,850.00	66,979
6/20/2016	Troy Allen Rhonemus	COO	Buy	7,800	$3.47	$27,066.00

(Data available from 1/1/2013 forward)

ChromaDex (NASDAQ CDXC) News Headlines

Source:

Date	Headline
	ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson ... globenewswire.com - April 23 at 4:28 PM
	ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director finance.yahoo.com - April 23 at 4:28 PM
	ChromaDex (CDXC) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 20 at 7:28 PM
	ChromaDex (CDXC) versus USANA Health Sciences (USNA) Head-To-Head Contrast www.americanbankingnews.com - April 20 at 1:26 AM
	Pre-Market Technical Scan on Chemicals Equities -- Celanese, ChromaDex, Rayonier Advanced Materials, and ... www.prnewswire.com - April 18 at 9:26 AM
	ChromaDex (CDXC) Downgraded to Strong Sell at Zacks Investment Research www.americanbankingnews.com - April 17 at 8:43 PM
	Critical Survey: Stada Arzneimittel (STDAF) and ChromaDex (CDXC) www.americanbankingnews.com - April 14 at 5:28 AM
	Analyzing Stada Arzneimittel (STDAF) & ChromaDex (CDXC) www.americanbankingnews.com - April 13 at 3:39 PM
	TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress feeds.benzinga.com - April 5 at 7:55 AM
	HC Wainwright Analysts Give ChromaDex (CDXC) a $8.00 Price Target www.americanbankingnews.com - April 2 at 9:34 AM
	Insider Selling: Chromadex Corp (CDXC) CEO Sells 24,578 Shares of Stock www.americanbankingnews.com - March 29 at 10:46 PM
	ChromaDex (CDXC) Announces Published Results from Human Clinical Study of NIAGEN www.streetinsider.com - March 29 at 9:49 AM
	New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health finance.yahoo.com - March 29 at 9:49 AM
	Chromadex (CDXC) Downgraded by BidaskClub to "Hold" www.americanbankingnews.com - March 28 at 12:34 AM
	Head-To-Head Comparison: Anthera Pharmaceuticals (ANTH) & Chromadex (CDXC) www.americanbankingnews.com - March 20 at 3:34 AM
	Chromadex (CDXC) Given a $8.00 Price Target at HC Wainwright www.americanbankingnews.com - March 18 at 9:22 PM
	Edited Transcript of CDXC earnings conference call or presentation 8-Mar-18 9:30pm GMT finance.yahoo.com - March 18 at 9:21 AM
	Chromadex (CDXC) Downgraded by ValuEngine to "Sell" www.americanbankingnews.com - March 11 at 3:19 PM
	Chromadex (CDXC) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - March 9 at 7:30 PM
	ChromaDex's (CDXC) CEO Frank Jaksch on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 9 at 9:58 AM
	Chromadex (CDXC) Releases Earnings Results, Misses Expectations By $0.14 EPS www.americanbankingnews.com - March 9 at 12:38 AM
	ChromaDex reports 4Q loss finance.yahoo.com - March 8 at 5:24 PM
	ChromaDex Corporation Reports 2017 Financial Results finance.yahoo.com - March 8 at 5:24 PM
	ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018 finance.yahoo.com - March 6 at 9:16 AM
	Chromadex (CDXC) to Release Quarterly Earnings on Thursday www.americanbankingnews.com - March 5 at 6:10 PM
	Chromadex (CDXC) PT Set at $8.00 by HC Wainwright www.americanbankingnews.com - March 5 at 2:58 PM
	Tieton Capital Management LLC Trims Holdings in Chromadex Corp (CDXC) www.americanbankingnews.com - February 27 at 4:14 PM
	Brokerages Anticipate Chromadex Corp (CDXC) to Announce -$0.01 Earnings Per Share www.americanbankingnews.com - February 26 at 10:48 AM
	Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov. finance.yahoo.com - February 20 at 9:04 AM
	BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board www.reuters.com - February 17 at 8:58 AM
	ChromaDex (CDXC) Chairman Stephen Allen to Retire from Board of Directors www.streetinsider.com - February 17 at 8:58 AM
	ChromaDex Chairman Stephen Allen Will Retire from Board of Directors finance.yahoo.com - February 16 at 4:37 PM
	Chromadex (CDXC) Cut to Sell at Zacks Investment Research www.americanbankingnews.com - February 12 at 7:18 PM
	ChromaDex (CDXC) Reports Prelim. 4Q Revenues Above Consensus, Prelim. FY18 Revenues Expected Below Estimates www.streetinsider.com - February 12 at 9:06 AM
	ChromaDex Corporation Reports Preliminary 2017 Results finance.yahoo.com - February 12 at 9:06 AM
	Chromadex (CDXC) Upgraded at BidaskClub www.americanbankingnews.com - February 11 at 9:36 AM
	Chromadex (CDXC) Given a $8.00 Price Target by HC Wainwright Analysts www.americanbankingnews.com - February 10 at 4:44 PM
	Chromadex (CDXC) Lifted to Hold at ValuEngine www.americanbankingnews.com - February 8 at 11:14 PM
	National Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s Disease finance.yahoo.com - February 8 at 8:53 AM
	ChromaDex to Present at the 3rd Annual NAD+ Summit finance.yahoo.com - February 1 at 9:16 AM
	Chromadex (CDXC) Lowered to "Sell" at BidaskClub www.americanbankingnews.com - January 27 at 3:58 PM
	ChromaDex (CDXC) Reports Denial by PTAB of Elysium Health's Challenge of ChromaDex Licensed '807' Patent - StreetInsider.com www.streetinsider.com - January 23 at 8:15 AM
	ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary - GlobeNewswire (press release) globenewswire.com - January 23 at 8:15 AM
	ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary finance.yahoo.com - January 23 at 8:15 AM
	BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent www.reuters.com - January 22 at 5:52 PM
	Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB) finance.yahoo.com - January 22 at 5:52 PM
	Chromadex's (CDXC) Buy Rating Reiterated at HC Wainwright www.americanbankingnews.com - January 16 at 8:08 AM
	Head-To-Head Contrast: Portola Pharmaceuticals (PTLA) vs. Chromadex (CDXC) www.americanbankingnews.com - January 13 at 5:06 PM
	Insider Selling: Chromadex Corp (CDXC) CEO Sells 28,379 Shares of Stock www.americanbankingnews.com - January 12 at 6:58 PM
	Wired News – ChromaDex Launched TRU NIAGEN(TM) in Singapore with Retail Partner Watsons finance.yahoo.com - January 10 at 10:00 AM

ChromaDex (NASDAQ:CDXC) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Financials are not available for this stock.

ChromaDex (NASDAQ CDXC) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff